Abstract
Hepatocellular Carsinoma (HCC) merupakan kanker hati primer yang paling sering ditemukan dan menjadi penyebab utama kematian akibat kanker di dunia. Alpha-fetoprotein (AFP) digunakan secara luas sebagai penanda tumor dalam diagnosis dan pemantauan HCC, di mana peningkatan kadar AFP diduga berkorelasi dengan derajat keparahan penyakit berdasarkan sistem klasifikasi Barcelona Clinic Liver Cancer (BCLC). Penelitian ini bertujuan untuk mengetahui hubungan antara kadar AFP dengan derajat keparahan HCC berdasarkan klasifikasi BCLC di RSUD dr. Zainoel Abidin Banda Aceh tahun 2024. Penelitian ini menggunakan desain observasional analitik dengan pendekatan cross-sectional, dengan data diperoleh dari rekam medis pasien HCC yang memenuhi kriteria inklusi. Sebanyak 40 pasien dijadikan sampel dan dibagi berdasarkan stadium BCLC (A–D), kemudian dianalisis menggunakan uji Kruskall Wallis karena data tidak berdistribusi normal. Hasil penelitian menunjukkan bahwa distribusi pasien terbanyak terdapat pada stadium BCLC B (37,5%) dengan mayoritas berjenis kelamin laki-laki dan rentang usia 14–74 tahun. Kadar AFP menunjukkan rentang luas (1,41–1000 ng/mL) dengan nilai yang meningkat seiring bertambahnya derajat BCLC dimana kadar AFP pada stadium A dan B yaitu 1,41-1000 ng/mL dan stadium C dan D yaitu 68,86-1000 ng/mL, serta terdapat perbedaan signifikan antara kadar AFP pada stadium A, B,C,dan D dengan p = 0,01. Penelitian ini menunjuukan terdapat hubungan bermakna antara kadar AFP dengan derajat keparahan HCC, di mana peningkatan kadar AFP pada stadium lanjut mencerminkan aktivitas tumor yang lebih agresif serta gangguan fungsi hati yang lebih berat. Pemeriksaan AFP dapat dijadikan indikator tambahan dalam menilai progresivitas HCC meskipun perlu dikombinasikan dengan penilaian klinis dan radiologis lainnya.
References
Ananda Muhamad Tri Utama (2022) ‘Analisis Kadar Glypican-3 (Gpc3) Dan Alpha-Fetoprotein (Afp) Pada Pasien Hepatocellular Carcinoma (Hcc)’, 9, pp. 356–363.
Aprilicia, G. et al. (2021) ‘Evaluasi Perbandingan Serum Alfa-Fetoprotein pada Pasien Karsinoma Hepatoseluler dengan Etiologi Non-Viral Comparative Evaluation of Alpha-Fetoprotein Serum in Hepatocellular Carcinoma Patients with Non-Viral Etiology’, Jurnal Penyakit Dalam Indonesia, 8(1), pp. 37–42.
Chi, X. et al. (2022) ‘A comparison of clinical pathologic characteristics between alpha-fetoprotein negative and positive hepatocellular carcinoma patients from Eastern and Southern China’, BMC gastroenterology, 22(1), p. 202.
Darmadi, D. and Ruslie, R.H. (2021) ‘Association between prothrombin induced by Vitamin K absence-II (PIVKA-II) and barcelona clinic liver cancer (BCLC) stage, tumor size, portal venous thrombosis in hepatocellular carcinoma patients’, Sains Malaysiana, 50(2), pp. 475–480.
Dong, B. et al. (2024) ‘Development of a machine learning-based model to predict prognosis of alpha-fetoprotein-positive hepatocellular carcinoma’, Journal of Translational Medicine, 22(1), p. 455.
El-Azab, G.I. et al. (2025) ‘Evaluation of screening program for hepatocellular carcinoma at a single center’, Egyptian Liver Journal, 15(1), pp. 4–11. Available at: https://doi.org/10.1186/s43066-025-00404-4.
Fadillah, F.R., Rotty, L.W.A. and Sugeng, C.E.C. (2024) ‘Hubungan Kadar Alpha Fetoprotein dengan Derajat Keparahan Karsinoma Hepatoseluler’, Medical Scope Journal, 7(1), pp. 74–79. Available at: https://doi.org/10.35790/msj.v7i1.54829.
Jearth, V. et al. (2022) ‘Correlation of clinicopathological profile, prognostic factors, and survival outcomes with baseline alfa-fetoprotein levels in patients with hepatocellular carcinoma: A biomarker that is bruised but not broken’, Journal of clinical and experimental hepatology, 12(3), pp. 841–852.
‘Journal of the American College of Radiology’ (2008) Journal of the American College of Radiology, p. 1. Available at: https://doi.org/10.1016/j.jacr.2007.10.020.
Kim, H., Jang, M. and Kim, E. (2025) ‘Exploring the Multifunctional Role of Alpha-Fetoprotein in Cancer Progression: Implications for Targeted Therapy in Hepatocellular Carcinoma and Beyond’, International Journal of Molecular Sciences, 26(10), p. 4863.
Lee, W.C. (2021) ‘Value of alpha-fetoprotein in hepatocellular carcinoma’, Translational Gastroenterology and Hepatology, 6, pp. 2019–2022. Available at: https://doi.org/10.21037/tgh.2019.12.19.
Liu, C. et al. (2024) ‘Prediction of survival and analysis of prognostic factors for patients with AFP negative hepatocellular carcinoma: a population-based study’, BMC Gastroenterology, 24(1), pp. 4–11. Available at: https://doi.org/10.1186/s12876-024-03185-z.
Liu, C., Wu, J. and Chang, Z. (2021) ‘Trends and age-period-cohort effects on the prevalence, incidence and mortality of hepatocellular carcinoma from 2008 to 2017 in Tianjin, China’, International Journal of Environmental Research and Public Health, 18(11), p. 6034.
Martinelle, E. et al. (2020) ‘Apa itu kanker hati?: Berdasarkan pada pedoman praktik klinis ESMO’, Indonesia Society of Hematology and Medical-Oncology, pp. 7–11.
Mazza, S. et al. (2024) ‘Prognostic Role of Basal Serum Alpha-Fetoprotein in Patients with Hepatocellular Carcinoma Suitable for Curative Treatment’, Medicina (Lithuania), 60(5), pp. 1–15. Available at: https://doi.org/10.3390/medicina60050692.
Mulla, N. et al. (2025) ‘The impact of alpha-fetoprotein (AFP), child-turcotte-pugh (CTP) score and disease staging on the survival of hepatocellular carcinoma (HCC) patients: a retrospective cohort from single oncology center’, Oncology Research, 33(1), pp. 149–160. Available at: https://doi.org/10.32604/or.2024.050903.
Nandiaty, A.F. and Farida, L.D. (2024) ‘Hepatocellular Carcinoma Situation in Indonesia: A Systematic Review of Clinical Staging and Histological Characteristics at the Time of Diagnosis’, International Journal of Medical Science and Clinical Research Studies, 04(10), pp. 1801–1806. Available at: https://doi.org/10.47191/ijmscrs/v4-i10-14.
Nevola, R. et al. (2023) ‘Gender Differences in the Pathogenesis and Risk Factors of Hepatocellular Carcinoma’, Biology, 12(7), pp. 1–25. Available at: https://doi.org/10.3390/biology12070984.
Parikh, N.D. et al. (2020) ‘Biomarkers for the early detection of hepatocellular carcinoma’, Cancer Epidemiology, Biomarkers & Prevention, 29(12), pp. 2495–2503.
RAMADHINI, A.S. (2022) ‘Korelasi Serum Alfa-Fetoprotein (AFP) dengan Tingkat Keparahan Karsinoma Hepatoseluler Berdasarkan Sistem Staging Barcelona Clinic Liver Cancer (BCLC) di RSUP Dr. Sardjito Yogyakarta’. Universitas Gadjah Mada.
Shi, H. et al. (2025) ‘Unusual phenomenon in advanced hepatocellular carcinoma: declining alpha-fetoprotein levels despite disease progression’, Discover Oncology, 16(1). Available at: https://doi.org/10.1007/s12672-025-02972-8.
Shi, J., Zhu, X. and Yang, J.-B. (2025) ‘Advances and challenges in molecular understanding, early detection, and targeted treatment of liver cancer’, World Journal of Hepatology, 17(1), p. 102273.
Torimura, T. and Iwamoto, H. (2022) ‘Treatment and the prognosis of hepatocellular carcinoma in Asia’, Liver International, 42(9), pp. 2042–2054.
Turshudzhyan, A. et al. (2023) ‘Alpha Feto-protein Expression Trends for Screening Early Hepatocellular Carcinoma’, Gene Expression, 22(2), pp. 109–114.
Ursu, C.-P. et al. (2024) ‘Prognostic Indicators of Overall Survival in Hepatocellular Carcinoma Patients Undergoing Liver Resection’, Cancers, 16(7), p. 1427.
Yang, C. et al. (2023) ‘Pre-to postoperative alpha-fetoprotein ratio-based nomogram to predict tumor recurrence in patients with hepatocellular carcinoma’, Frontiers in Oncology, 13, p. 1134933.
Zhang, X. et al. (2020) ‘Simple Clinical Metrics Enhance AFP to Effectively Identify Cirrhotic Patients With Complicating Hepatocellular Carcinoma at Various AFP Levels’, Frontiers in Oncology, 9(January), pp. 1–8. Available at: https://doi.org/10.3389/fonc.2019.01478.
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 Kamalya Ulfa, Desi Maghfirah, Vera Dewi Mulia, Rachmat Hidayat, Soraya Rezeki